HHIG - it seemed very clear that CD17 might (will
Post# of 148162
On CD16, they were very clear that they thought the interim analysis (around 116 or 160?) patients could be dynamite. That was exciting.
But, they were much less clear on the start date. "hopefully next week." But, really, they are waiting for Anvisa to review the IV stability information that was recently submittted. So, that could go fast, or it could go slow.
Is that a fair recap on these two trials?